Objectives: Toassess the safety and efficacy of 1 470 nm laser en bloc resection (ERBT) compared to transurethral resection of bladder tumor (TURBT) in the treatment of primary multiple non-muscle invasive bladder cancers (NMIBC). Methods: Clinical datafrom 57 patients with multiple primary NMIBC treated at the Department of Urology, Shantou Central Hospital from October 2020 to July 2022 were analyzed. Of these, 25 patients underwent 1 470 nm laser en bloc resection, and 32 underwent TURBT. Both groups received identical postoperative maintenance bladder irrigation chemotherapy. Perioperative clinical characteristics, specimen quality, perioperative complications, and recurrence rates were recorded and compared. Results: There were no differences with the preoperative characteristics between the patients in the two groups. The 1 470 nm laser group was superior than the TURBT group in terms of the postoperative bladder irrigation time（0.88±0.14 vs 1.24±0.53）, obturator nerve reflection（4% vs 21.82%）and bladder perforation（0 vs 15.64%）, with statistically significant differences (P<0.05). Detrusor was found in 88% of the 1 470 nm laser group and 46.87% of the pathological specimens in the TURBT group (P<0.05). After a mean follow-up of 10.8 (10-18) months, the recurrence rates outside the wound margin were 12% in laser group and 12.5% in TURBT group, and the in situ recurrence rates were 8% and 9.37% respectively. The recurrence rate did not differ significantly between two groups. Conclusions: The study indicates that 1 470 nm laser en bloc resection is a viable, safe, and effective alternative treatment for primary multiple non-muscle-invasive bladder tumors.